ECSP982669A - COMBINATION THERAPY TO ERADICATE DETECTABLE HCV-RNA IN PATIENTS WITH CHRONIC HETATITIS C INFECTION - Google Patents
COMBINATION THERAPY TO ERADICATE DETECTABLE HCV-RNA IN PATIENTS WITH CHRONIC HETATITIS C INFECTIONInfo
- Publication number
- ECSP982669A ECSP982669A ECSP982669A ECSP982669A EC SP982669 A ECSP982669 A EC SP982669A EC SP982669 A ECSP982669 A EC SP982669A EC SP982669 A ECSP982669 A EC SP982669A
- Authority
- EC
- Ecuador
- Prior art keywords
- rna
- infection
- detectable hcv
- combination therapy
- chronic
- Prior art date
Links
- 238000002648 combination therapy Methods 0.000 title abstract 2
- 230000001684 chronic effect Effects 0.000 title 1
- 208000015181 infectious disease Diseases 0.000 title 1
- 102000006992 Interferon-alpha Human genes 0.000 abstract 5
- 108010047761 Interferon-alpha Proteins 0.000 abstract 5
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 abstract 3
- 229960000329 ribavirin Drugs 0.000 abstract 3
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 abstract 3
- 208000020403 chronic hepatitis C virus infection Diseases 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Se describe el uso de ribavirina, interferón alfa, o una combinación de ribvirina e interferón alfa, para la fabricación de una composición farmacéutica para el tratamiento a un paciente que tenga infección por hepatitis C crónica para erradicar el VHC-ARN detectable mediante un método que consiste en: administrar una cantidad efectiva de ribavirina en asociación con una cantidad efectiva de interferón alfa, en donde el paciente es aquel que ha fallado en su respuesta a un curso previo de terapia con interferón alfa. Las composiciones pueden ser utilizadas en un método para el tratamiento a un paciente que presente infección por hepatitis C crónica, para erradicar el VHC-ARN detectable, que incluye una terapia en combinación utilizando una cantidad terapéuticamente efectiva de ribavirina y una terapéuticamente efectiva de interferón alfa durante un periodo desde 20 hasta 80 semanas.The use of ribavirin, alpha interferon, or a combination of ribvirin and alpha interferon, is described for the manufacture of a pharmaceutical composition for the treatment of a patient with chronic hepatitis C infection to eradicate detectable HCV-RNA by a method that consists of: administering an effective amount of ribavirin in association with an effective amount of interferon alpha, where the patient is one who has failed to respond to a previous course of interferon alpha therapy. The compositions can be used in a method of treating a patient with chronic hepatitis C infection, to eradicate detectable HCV-RNA, including combination therapy using a therapeutically effective amount of ribavirin and a therapeutically effective amount of interferon alpha. over a period of 20 to 80 weeks.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ECSP982669 ECSP982669A (en) | 1998-09-16 | 1998-09-16 | COMBINATION THERAPY TO ERADICATE DETECTABLE HCV-RNA IN PATIENTS WITH CHRONIC HETATITIS C INFECTION |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ECSP982669 ECSP982669A (en) | 1998-09-16 | 1998-09-16 | COMBINATION THERAPY TO ERADICATE DETECTABLE HCV-RNA IN PATIENTS WITH CHRONIC HETATITIS C INFECTION |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP982669A true ECSP982669A (en) | 1999-04-16 |
Family
ID=42043588
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECSP982669 ECSP982669A (en) | 1998-09-16 | 1998-09-16 | COMBINATION THERAPY TO ERADICATE DETECTABLE HCV-RNA IN PATIENTS WITH CHRONIC HETATITIS C INFECTION |
Country Status (1)
| Country | Link |
|---|---|
| EC (1) | ECSP982669A (en) |
-
1998
- 1998-09-16 EC ECSP982669 patent/ECSP982669A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO4970691A1 (en) | COMBINATION THERAPY TO ERADICATE DETECTABLE HCV-RNA IN PATIENTS WITH CHRONIC HEPATITIS C INFECTION | |
| AR019551A1 (en) | USE OF RIBAVIRINE IN COMBINATION WITH INTERFERON ALFA FOR THE MANUFACTURE OF A MEDICINAL PRODUCT FOR COMBINATION THERAPY TO ERADICATE HCV-RNA DETECTABLE IN PATIENTS NOT AFFECTED TO ANTIVIRAL TREATMENT THAT HAVE INFECTION OF CHRONIC HEPATITIS C | |
| BR9911076A (en) | Use of peg-ifn-alpha and ribavirin for the treatment of chronic hepatitis C | |
| AR021226A1 (en) | COMBINATORY THERAPY WITH RIBAVIRINA-INTERFERON ALFA TO ERADICATE DETECTABLE HCV-RNA IN THOSE PATIENTS WHO PRESENT INFECTION WITH CHRONIC HEPATITIS C | |
| WO2000037110A3 (en) | Ribavirin-pegylated interferon alfa induction hcv combination therapy | |
| BR0015974A (en) | Use of levetiracetam, pharmaceutical composition, use of a pharmaceutical composition and methods to treat a patient administered with an amount of at least one compound and a disease and to selectively potentiate the therapeutic effect of a compound | |
| CY1110078T1 (en) | INJECTIONS WITH IODIDATED POVIDON FOR WASTE HEALING | |
| BR9915546A (en) | Combination therapy of ribavirin-interferon alfa for the detection of detectable hcv-rna in patients with chronic hepatitis c infection | |
| ES2136167T3 (en) | IDEBENONE COMPOSITIONS TO TREAT ALZHEIMER'S DISEASE. | |
| DE69111974D1 (en) | Use of lithium for the treatment or prophylaxis of Molluscum contagiusum. | |
| BRPI0409699A (en) | methods of inducing the diuretic effect, inducing, maintaining or restoring the diuretic effect of a non-adenosine modifying diuretic, maintaining, restoring or improving renal function in a patient, inducing diuresis, preventing the onset of renal impairment in a patient with fluid or CHF overload, treating CHF patients and improving overall health outcomes, pharmaceutical composition and uses | |
| AR022116A1 (en) | COMBINATION THERAPY FOR RHCAVIRINE INDUCTION HCV - INTERFERON ALFA | |
| ES2104223T3 (en) | 2 - ((2- (N-ISOBUTYL-N-METHYL) AMINO) -BENCILSULFINIL) BENZMIDAZOLE AS ANTIMICROBIAL AGENT AGAINST HELICOBACTER PYLORI. | |
| KR900701309A (en) | Method of treating genital carcinoma by using liquid nitrogen and recombinant DNA human α interferon | |
| ECSP982669A (en) | COMBINATION THERAPY TO ERADICATE DETECTABLE HCV-RNA IN PATIENTS WITH CHRONIC HETATITIS C INFECTION | |
| KR870010871A (en) | Intraoperative Treatment of Basal Cell Carcinoma by Recombinant Human Alpha Interferon | |
| BR0113115A (en) | Hepatitis C treatment with thymosin, interferon and ribavirin | |
| ES2168772T3 (en) | USE OF HORMONE OF GROWTH IN COMPOSITIONS FOR THE TREATMENT OF HEART RESISTANCE TO INSULIN. | |
| AR013498A1 (en) | USE OF IFN-ALPHA AND AMANTADINE FOR THE TREATMENT OF CHRONIC HEPATITIS C USE OF IFN-ALPHA | |
| ECSP993178A (en) | COMBINATORY THERAPY WITH RIBARVIRINE-INTERFERON ALPHA TO ERADICATE HCV-DETECTABLE RNA IN THOSE PATIENTS WITH CHRONIC HEPATITIS C INFECTION | |
| AR013424A1 (en) | USE OF URIDINE FOR THE PREPARATION OF A USEFUL PHARMACEUTICAL COMPOSITION TO INHIBIT THE TOXICITY OF PIRIMIDINE ANALOGS |